Barely Significant
← all excerpts

Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model.

Res Pract Thromb Haemost · 2022 · PMC8925002 · PMID 35316941

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

a slight trendp > 0.05actually significant
30 Concomitant use of low‐dose marstacimab (0.5 mg/kg) and 100 U/kg aPCC showed a slight trend toward improvement in hemostasis: a 49.7% decrease in bleeding compared with vehicle‐treated mice ( p > 0.05).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.